Why Cardinal Health (CAH) is back in focus after its latest quarter

Cardinal Health (CAH) has moved back onto investors’ radar after its third quarter results showed a year-over-year decline in net income and a sizeable goodwill impairment tied to its Navista and ION unit.

These profit and impairment headlines came alongside large pharmaceutical distribution sales, ongoing share repurchases, and an updated dividend. Together, they provide several angles to reassess how the stock fits into a healthcare portfolio.

The share price is down about 13% over the past three months and 9% year to date. However, the 1 year total shareholder return of 26.98% and 3 year total shareholder return above 100% show that longer term momentum has been strong, even as the latest quarter, goodwill impairment and dividend update reset expectations.

If this mix of healthcare distribution scale and capital returns has your attention, it could be a good moment to see what else is moving across 33 healthcare AI stocks

With the share price under pressure, long term total returns still strong, a higher dividend and ongoing buybacks, investors are left with a simple question: is Cardinal Health still undervalued, or has the market already priced in future growth?

Most Popular Narrative: 24% Undervalued

Cardinal Health's most followed narrative puts fair value at $245.27 per share versus the last close of $186.35, so the story hinges on what justifies that gap.

The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare, underpinning diversified revenue growth and supporting margin expansion.

There is a full playbook sitting behind that valuation. Revenue assumptions, margin shifts, and shrinking share count all pull in the same direction. It may be useful to understand which of those levers carries the most weight in this narrative.

Result: Fair Value of $245.27 (UNDERVALUED)

However, this depends on Cardinal Health retaining key customer contracts and managing potential margin pressure from tighter regulation and reimbursement changes, which could divert earnings from their intended trajectory.

Another View: What P/E Says About The Story

The narrative fair value suggests Cardinal Health is materially undervalued, yet the current P/E of 28.1x sits above the US Healthcare industry at 23.2x, the peer average at 22.6x, and even slightly above the fair ratio of 27x. That premium hints at less margin of safety if expectations slip. The question is which signal you put more weight on.

Next Steps

With mixed signals on value and expectations, the next move is yours. Acting early means you can shape your own view using the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that better fit your goals, risk comfort, and timeframe across different parts of the market.

• Target income first by reviewing companies that stand out as potential 14 dividend fortresses for investors who want yield playing a bigger role in total return.
• Hunt for mispriced quality by scanning screener containing 23 high quality undiscovered gems that may not yet be widely followed but still show solid fundamentals.
• Prioritise resilience by focusing on 68 resilient stocks with low risk scores that could help anchor your portfolio when conditions become more volatile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.